GlassScriptPhysician profile
Sarad Raj Baral
NPI 1497713283
$2,237.76
in general payments reported to CMS, 2019-2025
31 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $233 · 2021: $301 · 2022: $121 · 2023: $350 · 2024: $445 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987 · Education: $85.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $986.74 |
| Education | $85.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $291.11 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $231.75 | 2019-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.91 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $157.25 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $138.92 | 2019-2024 | |
| Astellas Pharma US INC | $130.07 | 2019-2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $123.79 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.51 | 2023-2025 | |
| Abbvie INC. | $109.67 | 2021-2024 | |
| Novo Nordisk INC | $103.35 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $100.40 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $100.27 | 2019-2023 | Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $61.51 | 2023 | Ingrezza |
| Allergan, INC. | $55.47 | 2019 | |
| Amgen INC. | $48.23 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $33.05 | 2025 | Ibsrela |
| Lundbeck LLC | $30.07 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $25.05 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.71 | 2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $19.92 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.49 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.26 | 2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.96 | 2025 | Caplyta |
| Medtronic, INC. | $17.33 | 2023 | Vanta Adaptivestim |
| Amarin Pharma, INC. | $16.06 | 2020 | |
| Xeris Pharmaceuticals, INC. | $15.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.13 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.99 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $14.33 | 2023 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $14.26 | 2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarad Baral listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.